Hence, an improved understanding of the GR–Wnt signaling axis in regulating endothelial dysfunction will not only permit the development of novel therapeutic strategies but may also reduce the off-target side effects of glucocorticoids. This evidence concerns the gene NR3C1 and endothelial dysfunction.